Ricardo Gargini
Overview
Explore the profile of Ricardo Gargini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
4754
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Comitre-Mariano B, Segura-Collar B, Vellila-Alonso G, Contreras R, Henandez-Lain A, Valiente M, et al.
Theranostics
. 2025 Jan;
15(2):726-744.
PMID: 39744679
Glioblastoma IDH wild type (GBM IDH wt) has a poor prognosis and a strongly associated with inflammatory processes. Inflammatory molecules generate positive feedback with tumor cells fueling tumor growth as...
2.
Comitre-Mariano B, Vellila-Alonso G, Segura-Collar B, Mondejar-Ruescas L, Sepulveda J, Gargini R
J Neuroinflammation
. 2024 Nov;
21(1):304.
PMID: 39578808
The inflammatory processes that drive pathologies of the central nervous system (CNS) are complex and involve significant contributions from the immune system, particularly myeloid cells. Understanding the shared and distinct...
3.
Segura-Collar B, Hiller-Vallina S, Gargini R
Neuro Oncol
. 2024 Nov;
27(1):309-310.
PMID: 39546560
No abstract available.
4.
Rosa-Olmeda G, Villa M, Hiller-Vallina S, Chavarrias M, Pescador F, Gargini R
Sensors (Basel)
. 2024 Sep;
24(17).
PMID: 39275569
The digitization of pathology departments in hospitals around the world is now a reality. The current commercial solutions applied to digitize histopathological samples consist of a robotic microscope with an...
5.
de Dios O, Ramirez-Gonzalez M, Gomez-Soria I, Segura-Collar B, Manosalva J, Megias D, et al.
J Immunother Cancer
. 2024 Aug;
12(8).
PMID: 39214651
Background: Activating and inhibitory receptors of natural killer (NK) cells such as NKp, NKG2, or CLEC are highly relevant to cold tumors including glioblastoma (GBM). Here, we aimed to characterize...
6.
Segura-Collar B, Gargini R
Neuro Oncol
. 2024 Jun;
26(8):1540-1541.
PMID: 38885250
No abstract available.
7.
Hiller-Vallina S, Mondejar-Ruescas L, Caamano-Moreno M, Comitre-Mariano B, Alcivar-Lopez D, Sepulveda J, et al.
Neuro Oncol
. 2024 Feb;
26(7):1213-1227.
PMID: 38411438
Background: Glioblastoma (GBM) is a highly malignant brain tumor that affects men more often than women. In addition, the former shows a poorer survival prognosis. To date, the reason for...
8.
Segura-Collar B, Hiller-Vallina S, de Dios O, Caamano-Moreno M, Mondejar-Ruescas L, Sepulveda-Sanchez J, et al.
Acta Neuropathol Commun
. 2023 Jul;
11(1):116.
PMID: 37438824
No abstract available.
9.
Segura-Collar B, Hiller-Vallina S, de Dios O, Caamano-Moreno M, Mondejar-Ruescas L, Sepulveda-Sanchez J, et al.
Acta Neuropathol Commun
. 2023 May;
11(1):79.
PMID: 37165457
Glial-origin brain tumors, including glioblastomas (GBM), have one of the worst prognoses due to their rapid and fatal progression. From an oncological point of view, advances in complete surgical resection...
10.
Segura-Collar B, Jimenez-Sanchez J, Gargini R, Dragoj M, Sepulveda-Sanchez J, Pesic M, et al.
Neurooncol Adv
. 2022 Nov;
4(1):vdac155.
PMID: 36325374
Background: Temozolomide (TMZ) is an oral alkylating agent active against gliomas with a favorable toxicity profile. It is part of the standard of care in the management of glioblastoma (GBM),...